Schrödinger, Inc. is pleased to
announce the general availability of version 1.8 of the FirstDiscovery
suite, which contains breakthrough technologies designed to
accelerate the drug discovery process and reduce overall costs.
Leading pharmaceutical and drug discovery companies, including
Bristol-Myers Squibb, Boehringer-Ingelheim, and Albany Molecular,
have validated our
solution and integrated it into their discovery
processes for a distinct competitive advantage.
The unparalleled accuracy obtained using the FirstDiscovery suite
complements and can greatly enhance current drug discovery efforts.
Addressing some of the specific problems in experimental
drug design,
the FirstDiscovery suite:
reliably identifies lead compounds that meet stringent criteria
early in the drug discovery process,
supports experimental high-throughput screening (HTS), even
when it is otherwise too expensive, too time consuming, or not
available,
increases the quality of candidates that proceed into lead
optimization and development.
The FirstDiscovery suite includes Glide and QikProp, for high
throughput library screening via binding affinity or pharmacokinetic
properties, respectively. For lead optimization, FirstDiscovery includes
Liaison, which elucidates contributions to binding affinity for drug
candidates to within chemical accuracy, and QSite, which performs
in-depth analysis of active-site
chemistry. FirstDiscovery 1.8 is
available for the SGI IRIX and PC Linux platforms.